Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

Zgod Nov. 7 at 7:14 PM

$ACET HC Wainwright new price target of $9? I’d love to know where that comes from!

2 · Reply

MiltonMilkyMilkovich Nov. 7 at 3:44 PM

$ACET It is pretty simple. there are no tutes or hnw individuals left to buy this companys shares. they are not interested. the banks/analysts dont really give a shit about this company(if they did they would have supported it at $1 to help cure the bid deficiency for the company). and its easy to borrow for the rest of us who want to take it down to .20c to force tax loss sellers to dump their shares before eoy. the game!

0 · Reply

MoonShine007 Nov. 7 at 2:28 PM

$ACET How on earth does this ticker have all these high buy targets from institutions and still keep dripping? 🤔

1 · Reply

MiltonMilkyMilkovich Nov. 7 at 2:11 PM

$ACET hc wainwright has no sway in this stock

0 · Reply

skyman Nov. 7 at 12:45 PM

$ACET It's amusing, all these analysts with buy ratings with these price targets, with a rs, I guess they'll be correct lol

0 · Reply

JarvisFlow Nov. 7 at 12:38 PM

HC Wainwright & Co. has adjusted their stance on Adicet Bio ( $ACET ), setting the rating to Buy with a target price of 4 → 9.

3 · Reply

MarkHope340 Nov. 6 at 4:03 PM

$ACET maintains stability while investors monitor AI exposure. AITX’s innovative approach drives expansion orders and deepens recurring revenue foundations.

0 · Reply

OnTheFringe Nov. 6 at 12:14 PM

$ACET R/S is coming, sometimes it's actually a good thing.

4 · Reply

Haunting_Low Nov. 5 at 9:28 PM

$ACET The board are requesting stakeholders to approve an r/s no less than 1-5 or greater than 1-30 https://investor.adicetbio.com/sec-filings/sec-filing/pre-14a/0001193125-25-266928

0 · Reply

d_risk Nov. 5 at 9:23 PM

$ACET - Adicet Bio Inc. Common Stock - 10Q - Updated Risk Factors ACET’s 10-Q risk factors now center on ADI-001’s clinical and regulatory hurdles, expanded global and financial risks, new challenges in commercialization, data privacy, and AI compliance, while removing early-stage, manufacturing, and personnel risks; macroeconomic, geopolitical, and Regeneron partnership exposures are newly detailed. #Biotechnology #PartnershipRisk #GeopoliticalRisk #MacroeconomicRisk #AICompliance #DataPrivacy #GlobalExpansion #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ACET/10-Q/2025-11-05

0 · Reply

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 31, 2025, 4:59 PM EDT - 14 days ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2025, 7:00 AM EDT - 17 days ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

Oct 16, 2025, 7:00 AM EDT - 4 weeks ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 7, 2025, 12:35 PM EDT - 5 weeks ago

Adicet Bio, Inc. - Special Call

Oct 7, 2025, 11:05 AM EDT - 5 weeks ago

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Oct 7, 2025, 7:01 AM EDT - 5 weeks ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 6:45 AM EDT - 5 weeks ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Sep 30, 2025, 4:27 PM EDT - 6 weeks ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:01 PM EDT - 3 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

May 21, 2025, 4:00 PM EDT - 6 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 4:01 PM EDT - 6 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025, 7:00 AM EDT - 7 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 28, 2025, 4:30 PM EDT - 7 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 7 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 8 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 9 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 3, 2025, 7:00 AM EST - 9 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 9 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 10 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 10 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 11 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 11 months ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 11 months ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 19, 2024, 4:10 PM EDT - 1 year ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Zgod Nov. 7 at 7:14 PM

$ACET HC Wainwright new price target of $9? I’d love to know where that comes from!

2 · Reply

MiltonMilkyMilkovich Nov. 7 at 3:44 PM

0 · Reply

MoonShine007 Nov. 7 at 2:28 PM

$ACET How on earth does this ticker have all these high buy targets from institutions and still keep dripping? 🤔

1 · Reply

MiltonMilkyMilkovich Nov. 7 at 2:11 PM

$ACET hc wainwright has no sway in this stock

0 · Reply

skyman Nov. 7 at 12:45 PM

$ACET It's amusing, all these analysts with buy ratings with these price targets, with a rs, I guess they'll be correct lol

0 · Reply

JarvisFlow Nov. 7 at 12:38 PM

HC Wainwright & Co. has adjusted their stance on Adicet Bio ( $ACET ), setting the rating to Buy with a target price of 4 → 9.

3 · Reply

MarkHope340 Nov. 6 at 4:03 PM

$ACET maintains stability while investors monitor AI exposure. AITX’s innovative approach drives expansion orders and deepens recurring revenue foundations.

0 · Reply

OnTheFringe Nov. 6 at 12:14 PM

$ACET R/S is coming, sometimes it's actually a good thing.

4 · Reply

Haunting_Low Nov. 5 at 9:28 PM

$ACET The board are requesting stakeholders to approve an r/s no less than 1-5 or greater than 1-30 https://investor.adicetbio.com/sec-filings/sec-filing/pre-14a/0001193125-25-266928

0 · Reply

d_risk Nov. 5 at 9:23 PM

0 · Reply

Haunting_Low Nov. 5 at 9:08 PM

$ACET 2025 Q3 Results: https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-reports-third-quarter-2025-financial-results-and

0 · Reply